Singapore markets close in 1 hour 51 minutes

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
37.16-3.96 (-9.63%)
At close: 04:00PM EDT
37.20 +0.04 (+0.11%)
After hours: 06:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close41.12
Open40.63
Bid36.78 x 100
Ask37.53 x 100
Day's range36.09 - 40.80
52-week range3.03 - 49.87
Volume419,730
Avg. volume978,314
Market cap390.448M
Beta (5Y monthly)2.47
PE ratio (TTM)N/A
EPS (TTM)-10.31
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est55.00
  • GlobeNewswire

    Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

    Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumorsEmerging clinical profile from CSPC’s Phase 1 China study indicates differentiation from PADCEV NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002),

  • GlobeNewswire

    Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

    Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study on track to commence in Summer of 2024Pre-clinical data for CRB-913 presented at Obesity Week; IND filing on track by the end of 2024$127M of cash & investments at February 2, 2024; 3+ years of projected runway through Q1 2027Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., March

  • GlobeNewswire

    Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

    NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY. Details of the panel discussion are as follow: BMO Capital Markets Inaugural Obesity SummitPanel Title: Emerging Therapeutics LandscapeDate: Wednesda